Stocks Retreat as Investors Sift Through Earnings: Markets Wrap
This content was published on July 22, 2025 – 11:44 (Bloomberg) — Stocks slipped Tuesday while investors braced…
Mike Lynch’s estate owes Hewlett Packard £730m, judge rules
Hewlett-Packard is owed £730 million ($944 million) from the estate of the late Mike Lynch and his former…
Savills UK | Big 6 office markets record 1.73 million sq ft take-up in H1 2025
Glasgow and Edinburgh in particular have shown remarkable performance in H1 2025 with Glasgow’s take-up 32% higher than…
India IPOs to raise US$30 billion over the next 12 months, country’s top arranger says
The expansion in India’s initial public offerings (IPOs) is expected to continue, with companies poised to raise more…
European stocks set for another lower open as tariff uncertainty dents sentiment – CNBC
European stocks set for another lower open as tariff uncertainty dents sentiment CNBCEuropean shares softer as EU mulls US…
Asian markets are mixed and Japan’s shares slip after election leaves Ishiba’s future in doubt
Your support helps us to tell the story From reproductive rights to climate change to Big Tech, The…
Bitcoin’s UTXO Count Falls Sharply — Are Whales Prepping for a Big Move?
Bitcoin’s upward price trajectory has slightly cooled, with the asset now trading just below the $119,000 mark, reflecting…
Live updates: Miners lead ASX higher, Insignia jumps after takeover
55m agoTue 22 Jul 2025 at 2:42amMarket snapshotASX 200: +0.1% at 8,673 points (live values below)Australian dollar: flat…
Trade Brains Portal recommends two stocks for 22 July
The Sensex climbed 443 points, or 0.54%, to close at 82,200.34, while the Nifty 50 rose 122 points,…
Asia stock markets today: live updates
Japan’s Nikkei 225 share average rises in early trade Japan’s  rose in early trade Tuesday, as markets reopened after…
Stock market today: Live updates
Traders work on the floor of the New York Stock Exchange (NYSE) at the opening bell on July…
Interleukin-17 Inhibitors Market to Witness Strong Growth During the Forecast Period (2020-2034) Driven by Expanding Indications and Therapeutic Innovation
The interleukin-17 inhibitors market is expected to remain strong in rheumatology (psoriasis and arthritis), with potential expansion into…